Pharming Group N.V. (FRA:PHG)
Germany · Delayed Price · Currency is EUR | Market Cap | 759.57M +19.6% |
| Revenue (ttm) | 320.46M +15.2% |
| Net Income | 10.72M |
| EPS | 0.01 |
| Shares Out | n/a |
| PE Ratio | 70.87 |
| Forward PE | 17.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 10.00 |
| Previous Close | 10.60 |
| Day's Range | 10.00 - 10.20 |
| 52-Week Range | 7.85 - 17.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
News
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York. Thursday June 4, 2026 at 11:05 EDT/17:05 CEST.
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
Pharming Group Transcript: AGM 2026
The meeting highlighted strong 2025 financial results, strategic pipeline expansion, and robust governance. All shareholder proposals, including remuneration and share authorizations, were approved by large majorities. RUCONEST remains a key revenue driver amid market challenges.
Pharming Group Slides: FY 2026
Pharming Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 28, 2026.
Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency
(RTTNews) - Pharming Group (PHAR) announced that the European Commission granted marketing authorization for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, f...
Pharming’s Joenja granted marketing authorization by European Commission
Pharming (PHAR) Group announced that the European Commission has granted marketing authorization for Joenja, an oral, selective phosphoinositide 3-kinase delta inhibitor, for the treatment of activate...
Pharming Group Q1 Earnings Call Highlights
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planne...
Pharming price target lowered to $40 from $41 at Oppenheimer
Oppenheimer lowered the firm’s price target on Pharming (PHAR) to $40 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 results with…
Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026
(RTTNews) - Pharming Group N.V. (PHAR) will deliver multiple scientific presentations at the Clinical Immunology Society (CIS) 2026 Annual Meeting, taking place May 6-9, 2026, in New Orleans.
Pharming Group Reports Lower Q1 Revenue, Highlights Joenja Growth And Regulatory Progress
(RTTNews) - Pharming Group N.V. (PHAR) reported its first-quarter 2026 financial results, showing lower total revenue year over year but strong growth from Joenja (Ieniolisib), alongside continued reg...
Pharming Group Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 8% year-on-year due to expected RUCONEST headwinds, while Joenja grew 34% with strong U.S. and international momentum. Regulatory progress and disciplined cost management support reaffirmed 2026 guidance and pipeline advancement.
Pharming Group Earnings release: Q1 2026
Pharming Group released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Pharming Group Slides: Q1 2026
Pharming Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinica...
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.
Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings
Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial r...
Pharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.
Pharming Group Transcript: 25th Annual Needham Virtual Healthcare Conference
The company reported strong 2025 revenue growth and set 2026 guidance for continued expansion, driven by RUCONEST and Joenja. Key pipeline milestones include phase II readouts for Joenja in higher prevalent PIDs and pivotal data for napazimone, supporting a strategy to scale in rare diseases.
Pharming Group Slides: 25th Annual Needham Virtual Healthcare Conference
Pharming Group has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Pharming initiated with a Buy at Canaccord on growth potential
As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Pharming (PHAR) with a Buy rating and $37 price target Lead product Ruconest, a complex biologic approved in the U.S.
Pharming initiated with a Buy at Canaccord
Canaccord analyst Whitney Ijem initiated coverage of Pharming (PHAR) with a Buy rating and $37 price target
Pharming Group to participate in April investor conferences
Pharming announced that management will participate in investor conferences Needham Virtual Healthcare and Kempen Life Sciences Conferences in April 2026.
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended ...
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficienc...